Clinical Significance of CA125 Level After the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2016 Mar 22

PMID 26996555

Citations 13

Authors

Maria Lee

Min Young Chang

Hanna Yoo

Kyung Eun Lee

Doo Byung Chay

Hanbyoul Cho

Sunghoon Kim

Young Tae Kim

Jae-Hoon Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine the most powerful cancer antigen 125 (CA125)-related prognostic factor for advanced epithelial ovarian cancer (EOC) and to identify cut-off values that distinguish patients with a poor prognosis from those with a good prognosis.

Materials And Methods: We included 223 patients who received staging laparotomy and were diagnosed with stage IIC-IV serous EOC. Cox regression analysis was used to determine the most significant prognostic factor among the following variables: serum CA125 before surgery and after the first, second, and sixth cycles of chemotherapy; the nadir CA125 value; the relative percentage change in CA125 levels after the first and second cycles of chemotherapy compared to baseline CA125; CA125 half-life; time to nadir; and time to normalization of the CA125 level.

Results: The CA125 level after the first chemotherapy cycle was the most significant independent prognostic factor for overall survival (OS). Time to normalization (p=0.028) and relative percentage change between CA125 levels at baseline and after the first chemotherapy cycle (p=0.021) were additional independent prognostic factors in terms of OS. The CA125 level after the first chemotherapy cycle (p=0.001) and time to normalization (p<0.001) were identified as independent prognostic factors for progression free survival (PFS).

Conclusion: Among well-established CA125-related prognostic factors, serum CA125 levels after the first cycle of chemotherapy and time to normalization were the most significant prognostic factors for both OS and PFS.

Citing Articles

Duodenal obstruction in a 38-year-old: Case report of an unusual ovarian cancer presentation requiring a Whipple procedure.

Somasegar S, Tostrud L, Poultsides G, Renz M Heliyon. 2024; 10(16):e36581.

PMID: 39262961 PMC: 11388602. DOI: 10.1016/j.heliyon.2024.e36581.

The effect of tinzaparin on biomarkers in FIGO stages III-IV ovarian cancer patients undergoing neoadjuvant chemotherapy - the TABANETOC trial: study protocol for a randomized clinical multicenter trial.

Karlsson A, Lindahl G, Holm A, Bergmark K, Dahm Kahler P, Fekete B Acta Oncol. 2024; 63:581-585.

PMID: 39037076 PMC: 11332459. DOI: 10.2340/1651-226X.2024.40207.

Effect of different treatment modalities on the prognosis of stage IV epithelial ovarian cancer: analysis of the SEER database.

Zhang S, Zhang H, Jia N, Suo S, Guo J BMC Womens Health. 2024; 24(1):345.

PMID: 38877551 PMC: 11179217. DOI: 10.1186/s12905-024-03199-5.

Spotlight on New Hallmarks of Drug-Resistance towards Personalized Care for Epithelial Ovarian Cancer.

Frezzini S, Lonardi S Cells. 2024; 13(7.

PMID: 38607050 PMC: 11011744. DOI: 10.3390/cells13070611.

Tumor Markers and Their Diagnostic Significance in Ovarian Cancer.

Matsas A, Stefanoudakis D, Troupis T, Kontzoglou K, Eleftheriades M, Christopoulos P Life (Basel). 2023; 13(8).

PMID: 37629546 PMC: 10455076. DOI: 10.3390/life13081689.

References

Tate S, Hirai Y, Takeshima N, Hasumi K . CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol. 2004; 96(1):143-9. DOI: 10.1016/j.ygyno.2004.09.020. View

Lee C, Friedlander M, Brown C, Gebski V, Georgoulopoulos A, Vergote I . Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. J Natl Cancer Inst. 2011; 103(17):1338-42. DOI: 10.1093/jnci/djr282. View

Paramasivam S, Tripcony L, Crandon A, Quinn M, Hammond I, Marsden D . Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol. 2005; 23(25):5938-42. DOI: 10.1200/JCO.2005.08.151. View

Riedinger J, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau J . CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol. 2006; 17(8):1234-8. DOI: 10.1093/annonc/mdl120. View

Hogdall E, Christensen L, Kjaer S, Blaakaer J, Kjaerbye-Thygesen A, Gayther S . CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol. 2006; 104(3):508-15. DOI: 10.1016/j.ygyno.2006.09.028. View

Riedinger J, Bonnetain F, Basuyau J, Eche N, Larbre H, Dalifard I . Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol. 2007; 18(5):881-5. DOI: 10.1093/annonc/mdl500. View

Liu P, Alberts D, Monk B, Brady M, Moon J, Markman M . An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007; 25(24):3615-20. DOI: 10.1200/JCO.2006.09.4540. View

Prat A, Parera M, Peralta S, Perez-Benavente M, Garcia A, Gil-Moreno A . Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol. 2007; 19(2):327-31. DOI: 10.1093/annonc/mdm495. View

Riedinger J, Eche N, Basuyau J, Dalifard I, Hacene K, Pichon M . Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study. Gynecol Oncol. 2008; 109(2):194-8. DOI: 10.1016/j.ygyno.2008.01.035. View

10.

Le T, Faught W, Hopkins L, Fung-Kee-Fung M . Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer. J Obstet Gynaecol Can. 2008; 30(8):665-670. DOI: 10.1016/S1701-2163(16)32914-0. View

11.

. Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol. 1987; 156(1):263-4. View

12.

Wong C, Dai Z, Lele S, Natarajan N . Comparison of CA 125 after three courses of chemotherapy and results of second-look surgery. Eur J Gynaecol Oncol. 2000; 21(1):70-3. View

13.

Colakovic S, Lukic V, Mitrovic L, Jelic S, Susnjar S, Marinkovic J . Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers. 2000; 15(2):147-52. DOI: 10.1177/172460080001500204. View

14.

Bocker W . [WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics]. Verh Dtsch Ges Pathol. 2003; 86:116-9. View

15.

Rustin G, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A . Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004; 96(6):487-8. DOI: 10.1093/jnci/djh081. View

16.

Gadducci A, Cosio S, Fanucchi A, Negri S, Cristofani R, Genazzani A . The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol. 2004; 93(1):131-6. DOI: 10.1016/j.ygyno.2003.12.043. View

17.

Rustin G . Can we now agree to use the same definition to measure response according to CA-125?. J Clin Oncol. 2004; 22(20):4035-6. DOI: 10.1200/JCO.2004.06.628. View

18.

Buller R, Berman M, Bloss J, Manetta A, Disaia P . CA 125 regression: a model for epithelial ovarian cancer response. Am J Obstet Gynecol. 1991; 165(2):360-7. DOI: 10.1016/0002-9378(91)90093-7. View

19.

Buller R, Berman M, Bloss J, Manetta A, Disaia P . Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol. 1992; 47(1):87-92. DOI: 10.1016/0090-8258(92)90082-t. View

20.

Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T . Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol. 1995; 58(1):42-7. DOI: 10.1006/gyno.1995.1181. View